<code id='F04241FB2E'></code><style id='F04241FB2E'></style>
    • <acronym id='F04241FB2E'></acronym>
      <center id='F04241FB2E'><center id='F04241FB2E'><tfoot id='F04241FB2E'></tfoot></center><abbr id='F04241FB2E'><dir id='F04241FB2E'><tfoot id='F04241FB2E'></tfoot><noframes id='F04241FB2E'>

    • <optgroup id='F04241FB2E'><strike id='F04241FB2E'><sup id='F04241FB2E'></sup></strike><code id='F04241FB2E'></code></optgroup>
        1. <b id='F04241FB2E'><label id='F04241FB2E'><select id='F04241FB2E'><dt id='F04241FB2E'><span id='F04241FB2E'></span></dt></select></label></b><u id='F04241FB2E'></u>
          <i id='F04241FB2E'><strike id='F04241FB2E'><tt id='F04241FB2E'><pre id='F04241FB2E'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:9573
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more
          Diversifying clinical trials isn't enough to close racial gaps: study
          Diversifying clinical trials isn't enough to close racial gaps: study

          AdobeParticipationinaclinicaltrialisoftenconsideredsomethingofanequalizerinmedicine.Researchershavep

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Pharma patents targeted by Biden in move to slash drug prices

          PresidentBidenMANDELNGAN/AFPviaGettyImagesWASHINGTON—TheWhiteHouseisthrowingitssupportbehindacontrov